Overview

A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-03-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.
Phase:
PHASE1
Details
Lead Sponsor:
Incyte Corporation
Treatments:
Cetuximab